Clinical Trials

A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first…
Read More...

Novartis announced Kisqali (ribociclib) achieved statistically significant improvement in overall survival in the Phase III MONALEESA-3 clinical trial. This is the second Phase III…
Read More...

Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials…
Read More...

WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring and neuromodulation, has enrolled its first patient in the pivotal clinical study of…
Read More...

Exelixis, Inc. announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) versus…
Read More...

Barc Lab and OWL Metabolomics announced that they have entered into a global strategic partnership combining Barc Lab's industry leading central lab services with OWL Metabolomics'…
Read More...

BioArctic AB (publ) announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805. The Phase 1 study in…
Read More...

Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high…
Read More...

Moderna, Inc., announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in…
Read More...

The pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with…
Read More...

Verseon’s phase 1 trial in healthy volunteers, which started dosing last week, could lead to a new treatment standard for millions of cardiac patients who would benefit from long-term…
Read More...

Genentech announced the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with…
Read More...

Concert Pharmaceuticals announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive…
Read More...

Ironwood Pharmaceuticals announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, controlled, Phase…
Read More...

AbbVie announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung…
Read More...

CRISPR Therapeutics and MaxCyte announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics…
Read More...

Genkyotex announced that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary and secondary interim efficacy endpoints with high statistical significance after…
Read More...

MaaT Pharma announced the dosing of the first patient in a Phase 2 clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute…
Read More...

Bristol-Myers Squibb Company and Compugen announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an…
Read More...